NL-OMON21157已完成4 期
Prevalence of unmet target LDL-C recommendations in very high risk patients despite high intensity lipid modifying therapy
WC0 个研究点目标入组 1,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Opname voor ACS: (N)STEMI type I |
排除标准
- •- Leeftijd <18 jaar |
研究者
相似试验
已完成
4 期
Prevalence of unmet target LDL-C recommendations in very high risk patients despite high intensity lipid modifying therapyHyperlipidaemia/ high cholesterol post myocardial infarction10003216NL-OMON55816WCN (Werkgroep Cardiologische centra Nederland)1,000
已完成
3 期
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-CholesterolHyperlipidemiaNCT00136942Pfizer's Upjohn has merged with Mylan to form Viatris Inc.370
已完成
不适用
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCIHyperlipidemiasCoronary Artery DiseaseNCT06338956Samsung Medical Center135,877
尚未招募
Unknown
Optimal target LDL level for small vessel occlusion stroke: A multi-center, prospective, randomized, open-label, blinded endpoint trial (SVO70)Diseases of the circulatory systemKCT0009043Seoul National University Hospital4,016
已完成
不适用
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in SpainDyslipaemiaAtherosclerosis RiskIncreased hsCRPInflammatory and Oxidative Status in the Spanish PopulationNCT00998062AstraZeneca30,181